George Kumar, Senior Director at AstraZeneca, shared a post on LinkedIn about a paper by Matthew D. Galsky et al. published in the Journal of Clinical Oncology:
“Muscle-Invasive Bladder Cancer: A Watershed Moment.
Excellent review article.
Summary
Treatment of muscle-invasive bladder cancer (MIBC) has advanced considerably but remains challenging due to the older, comorbid patient population in whom trial results often fail to translate fully into real-world effectiveness.
Current standards include radical cystectomy with perioperative systemic therapy or chemoradiation. Recently, immune checkpoint blockade (ICB) has been incorporated into both neoadjuvant and adjuvant settings, with ongoing trials exploring circulating tumor DNA to guide adjuvant ICB use.
Antibody–drug conjugates combined with ICB are also emerging in perioperative care. Improved systemic regimens with higher complete response rates are enabling exploration of risk-adapted, bladder-sparing strategies. The field is entering a transformative era where new therapeutics, precise biomarkers, and individualized strategies could redefine MIBC management.”
Title: Muscle-Invasive Bladder Cancer: A Watershed Moment
Authors: Matthew D. Galsky, Leslie Ballas, Ashish M. Kamat
You can read the Full Article in the Journal of Clinical Oncology.
More posts featuring George L. Kumar on OncoDaily.